BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological ...
The Units may be offered for sale to prospective investors (each, an “Investor”) (i) in all provinces and territories of Canada pursuant to available prospectus exemptions, (ii) in the United States ...
The gross proceeds from the offering are expected to be approximately $3.13 million, excluding any proceeds that may be received upon exercise of the warrants and before deducting the placement ...
The company plans to use the proceeds to support exploration at the Lunahuasi project in Argentina and the Los Helados ...
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical ...
Core Nickel Corp. (CSE: CNCO) ("Core Nickel" or the "Company") announces that it proposes to undertake an up to $175,000 ...
Bioscience Corp. (Nasdaq:LEXX; LEXXW), a developer of drug delivery platforms, today announced that it has closed a ...